Chiara Bertagnin

Dr. Chiara Bertagnin

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MPMaria Chiara Pismataro
Maria Chiara Pismataro
Tommaso FelicettiTommaso Felicetti
Tommaso Felicetti
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
MNMaria Giulia Nizi
Maria Giulia Nizi
ABAnna Bonomini
Anna Bonomini
Serena MassariSerena Massari
Serena Massari

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Serena MassariSerena Massari
Serena Massari
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
MPMaria Chiara Pismataro
Maria Chiara Pismataro
ADAnna Donnadio
Anna Donnadio
Giulio NannettiGiulio Nannetti
Giulio Nannetti
OTOriana Tabarrini
Oriana Tabarrini

1 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RJRuifang Jia
Ruifang Jia
JZJian Zhang
Jian Zhang
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
SCSrinivasulu Cherukupalli
Srinivasulu Cherukupalli
WAWei Ai
Wei Ai
XLXinyong Liu
Xinyong Liu

31 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MCMarta Celegato
Marta Celegato
LMLorenzo Messa
Lorenzo Messa
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
BMBeatrice Mercorelli
Beatrice Mercorelli
ALArianna Loregian
Arianna Loregian
High-risk human papillomaviruses (HR-HPV) are the etiological agents of almost all cervical cancer cases and a high percentage of head-and-neck malignancies. Although HPV vaccination can reduce cancer incidence, its coverage significantly differs among countries, and, therefore, in the next decades HPV-related tumors will not likely be eradicated worldwide. Thus, the need of specific treatments persists, since no anti-HPV drug is yet available. We recently discovered a small molecule (Cpd12) able to inhibit the E6-mediated degradation of p53 through the disruption of E6/p53 binding in HPV16- and HPV18-positive cervical cancer cells. By employing several biochemical and cellular assays, here we show that Cpd12 is also active against cervical cancer cells transformed by other HR-HPV strains, such as HPV68 and HPV45, and against a HPV16-transformed head-and-neck cancer cell line, suggesting the possibility to employ Cpd12 as a targeted drug against a broad range of HPV-induced cancers. In these cancer cell lines, the antitumoral mechanism of action of Cpd12 involves p53-dependent cell cycle arrest, a senescent response, and inhibition of cancer cell migration. Finally, we show that Cpd12 can strongly synergize with taxanes and topoisomerase inhibitors, encouraging the evaluation of Cpd12 in preclinical studies for the targeted treatment of HPV-related carcinomas.

31 July 2023 in Cancer Letters
Verified
Journal Article
Open access
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
LMLorenzo Messa
Lorenzo Messa
Matteo PavanMatteo Pavan
Matteo Pavan
MCMarta Celegato
Marta Celegato
Mattia SturleseMattia Sturlese
Mattia Sturlese
ALArianna Loregian
Arianna Loregian
Human papillomavirus (HPV)-induced cancers still represent a major health issue for worldwide population and lack specific therapeutic regimens. Despite substantial advancements in anti-HPV vaccination, the incidence of HPV-related cancers remains high, thus there is an urgent need for specific anti-HPV drugs. The HPV E7 oncoprotein is a major driver of carcinogenesis that acts by inducing the degradation of several host factors. A target is represented by the cellular phosphatase PTPN14 and its E7-mediated degradation was shown to be crucial in HPV oncogenesis. Here, by exploiting the crystal structure of E7 bound to PTPN14, we performed an in silico screening of small-molecule compounds targeting the C-terminal CR3 domain of E7 involved in the interaction with PTPN14. We discovered a compound able to inhibit the E7/PTPN14 interaction in vitro and to rescue PTPN14 levels in cells, leading to a reduction in viability, proliferation, migration, and cancer-stem cell potential of HPV-positive cervical cancer cells. Mechanistically, as a consequence of PTPN14 rescue, treatment of cancer cells with this compound altered the Yes-associated protein (YAP) nuclear-cytoplasmic shuttling and downstream signaling. Notably, this compound was active against cervical cancer cells transformed by different high-risk (HR)-HPV genotypes indicating a potential broad-spectrum activity. Overall, our study reports the first-in-class inhibitor of E7/PTPN14 interaction and provides the proof-of-principle that pharmacological inhibition of this interaction by small-molecule compounds could be a feasible therapeutic strategy for the development of novel antitumoral drugs specific for HPV-associated cancers.

13 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LMLorenzo Messa
Lorenzo Messa
MCMarta Celegato
Marta Celegato
Chiara BertagninChiara Bertagnin
Chiara Bertagnin
BMBeatrice Mercorelli
Beatrice Mercorelli
Gualtiero AlvisiGualtiero Alvisi
Gualtiero Alvisi
ALArianna Loregian
Arianna Loregian
Human papillomavirus is the most common viral infectious agent responsible for cancer development in humans. High-risk strains are known to induce cancer through the expression of the viral oncogenes E6 and E7, yet we have only a partial understanding of the precise mechanisms of action of these viral proteins. Here we investigated the molecular mechanism through which the oncoprotein E6 alters the Hippo-YAP/TAZ pathway to trigger YAP/TAZ induction in cancer cells. By employing E6 overexpression systems combined with protein–protein interaction studies and loss-of-function approaches, we discovered that the E6-mediated targeting of hScrib, which supports YAP/TAZ upregulation, intimately requires E6 homodimerization. We show that the self-association of E6, previously reported only in vitro, takes place in the cytoplasm and, as a dimer, E6 targets the fraction of hScrib at the cell cortex for proteasomal degradation. Thus, E6 homodimerization emerges as an important event in the mechanism of E6-mediated hScrib targeting to sustain downstream YAP/TAZ upregulation, unraveling for the first time the key role of E6 homodimerization in the context of its transforming functions and thus paving the way for the possible development of E6 dimerization inhibitors.